The triglyceride response to GLP-1 receptor agonists is actually one of the most robust and consistent findings in the clinical trial data. The SUSTAIN and STEP programs both showed significant TG reductions, and mechanistically it makes sense — GLP-1 RAs reduce hepatic VLDL production, improve insulin sensitivity (which reduces de novo lipogenesis), and reduce free fatty acid flux to the liver.
In the OP's case, the 45 lbs of weight loss is clearly the dominant driver, but there's likely a direct hepatic effect from semaglutide on top of that. The VLDL reduction of 60% mirrors the TG drop perfectly, as expected since VLDL is the primary triglyceride carrier.
Given the improvement, I'd recommend repeating the panel at 12 months to confirm stability, and asking about an ApoB level to get a more complete picture of residual risk.
I didn't even know triglycerides were important until I joined this forum. My last test was 187 and my doctor just said "a little high." After reading threads like this I realize I should be paying more attention. Starting to understand why people here say the weight loss is almost secondary to the metabolic improvements.
That's exactly right. If I hadn't lost a single pound but had these lipid changes, it would still be a massive win for my cardiovascular health. The weight loss is the visible transformation but the invisible transformation — what's happening inside your blood vessels and liver — is where the real years of life are gained.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference Standards